Bristol-Myers Squibb Company · BMY · FY2026 Q1 · Calendar Q2 2026

Bristol-Myers Squibb Beats Q1 Estimates as Oncology Pipeline Accelerates

Bristol-Myers Squibb posted a convincing Q1 2026 beat, with EPS of $1.58 (vs. $1.42 consensus, +11.3%) and revenue of $11.5B (vs. $10.9B consensus, +5.1%). Growth was anchored by double-digit expansion in early-life-cycle oncology assets Breyanzi and Opdualag, while the pipeline delivered tangible milestones: FDA breakthrough therapy designation for iberdomide (PDUFA August 17), positive Phase III interim data for an ADC in triple-negative breast cancer, and advancing late-stage readouts for Milvexian and oral CELMoDs. Management reaffirmed full-year guidance at the upper end of the range, backed by AI-driven R&D cycle-time reductions and disciplined capital allocation. The stock gained 5.2% on the report but has since drifted roughly 5.6% lower, and at $63.60 trades nearly in line with the $63.25 consensus target, suggesting the market is waiting for pipeline catalysts to materialize…

Reported Before market openNYSEHealthcare $127.75B market cap
90quality score

Company context

Snapshot as of publication

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults.…

Earnings scorecard

Reported versus consensus
Reported EPS $1.58 Consensus $1
EPS surprise +11.3% Reported versus consensus
Reported revenue $11.49B Consensus $10.93B
Revenue surprise +5.1% Reported versus consensus

Market reaction

prior-close to event-session close
Stock move +5.2% Event window
SPY move +1.0% Same window
Abnormal move +4.2% Stock minus SPY
Volume 2.8× Versus trailing sessions
Subsequent drift -5.6% Up to 20 sessions
BMYSPY benchmark

Follow BMY with an agent that reads every filing, transcript, and price print. Free to start.

Try FN2 free

Transcript intelligence

What changed

New this quarter: iberdomide received FDA breakthrough therapy designation and priority review with a PDUFA date of August 17; positive Phase III interim data for an ADC in previously treated triple-negative breast cancer was presented in China; a new focused study for Camzyos in non-obstructive hypertrophic cardiomyopathy was announced; and the company disclosed two acquisitions, one to obtain the Cobenfy asset and another adding an mRNA in-vivo platform to expand cell-therapy capabilities.

Guidance delta

Full-year 2026 guidance was reaffirmed. Management expressed confidence in meeting the upper end of the range, citing continued execution, AI-driven R&D efficiencies, and pipeline progress.

Key takeaways

  • Q1 revenue of $11.5B beat consensus by 5.1%, and EPS of $1.58 beat by 11.3%, driven by double-digit growth in Breyanzi and Opdualag.
  • Pipeline momentum is strong: iberdomide received FDA breakthrough therapy designation with an August 17 PDUFA date, and positive Phase III interim ADC data was presented in triple-negative breast cancer.
  • Full-year guidance was reaffirmed at the upper end of the range.
  • AI and laboratory automation initiatives aim to reduce drug development cycle times by 30%.
  • Business-development capital remains available for strategic acquisitions, as evidenced by two recent deals for Cobenfy and an mRNA in-vivo platform.

Management priorities

  • Present full Phase III data for ADCs and oral CELMoDs at ASCO.
  • Launch and expand market uptake of Pumitamig across multiple oncology indications.
  • Initiate a focused trial of Camzyos in non-obstructive hypertrophic cardiomyopathy.
  • Accelerate AI and laboratory automation investments to further reduce cycle times.
  • Continue evaluating strategic M&A opportunities aligned with core therapeutic areas.

Related earnings events

Healthcare
TMO · FY2026 Q2 · Calendar Q3 2026TMO Q2 2026: Revenue Up 10%, EPS Up 13% as Guidance Rises Again

Sources

  1. Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
  2. FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
  3. Polygon adjusted daily market bars · 2026-07-28T22:21:10.411547+00:00
  4. Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-28T22:21:10.408544+00:00

Methodology

Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.

Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.